German company BAYER can now go ahead with the € 16.3 billion purchase (86 euros per share) of the SCHERING laboratory, following MERCK's pulling out of the race and refusal to improve on its offer of 77 euros per share. This operation will give birth to BAYER-SCHERING PHARMACEUTICALS, which will have a turnover of almost € 15 billion in the health sector, 9 billion of which from pharmaceuticals.